3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoplasms
1
Myelodysplastic Syndromes
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Prolymphocytic, B-Cell
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Biphenotypic, Acute
1
Kidney Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Burkitt Lymphoma
1
Interventions
pembrolizumab
23
Carboplatin
23
Paclitaxel
17
Specimen Handling
15
Magnetic Resonance Spectroscopy
11
Cyclophosphamide
10
Biopsy
10
Taxes
7
Capecitabine
7
Nivolumab
6
130-nm albumin-bound paclitaxel
6
sacituzumab govitecan
5
Gemcitabine
5
Doxorubicin
5
Albumin-Bound Paclitaxel
5
Fulvestrant
4
olaparib
3
fludarabine
3
eribulin
3
durvalumab
3
atezolizumab
3
Letrozole
3
Epirubicin
3
Bevacizumab
3
veliparib
2
poly ICLC
2
pertuzumab
2
aldesleukin
2
abemaciclib
2
Trastuzumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Blood Component Removal
×
30 days
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled